Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

VEGF In Systemic Circulation Of ROP-infants

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
Andreas Stahl, MD, University Hospital Freiburg
ClinicalTrials.gov Identifier:
NCT01470430
First received: November 9, 2011
Last updated: January 26, 2014
Last verified: January 2014

November 9, 2011
January 26, 2014
March 2012
March 2014   (final data collection date for primary outcome measure)
Systemic VEGF levels following treatment [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
comparing VEGF levels in serum of ROP infants treated with intravitreal anti-VEGF agents vs. retinal laser photocoagulation over 16 weeks post treatment
Systemic VEGF levels following treatment [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
comparing VEGF levels in serum of ROP infants treated with intravitreal bevacizumab vs. retinal laser photocoagulation over 16 weeks post treatment
Complete list of historical versions of study NCT01470430 on ClinicalTrials.gov Archive Site
Systemic levels of other growth factors (e.g. IGF-1) [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
comparing systemic levels of other (non-VEGF) factors in serum of ROP infants treated with intravitreal anti-VEGF agents vs. retinal laser photocoagulation
Systemic levels of other growth factors (e.g. IGF-1) [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
comparing systemic levels of other (non-VEGF) factors in serum of ROP infants treated with intravitreal bevacizumab vs. retinal laser photocoagulation
Not Provided
Not Provided
 
VEGF In Systemic Circulation Of ROP-infants
Study to Measure Systemic VEGF Levels in ROP Infants Following Intravitreal Anti-VEGF Therapy or Retinal Laser Treatment

The purpose of this study is to measure systemic levels of vascular endothelial growth factor (VEGF) and other proteins (e.g. IGF-1) in the systemic circulation of infants with retinopathy of prematurity (ROP) following ocular treatment with either intravitreal injections of anti-VEGF agents or retinal laser photocoagulation. The primary aim is to determine if serum VEGF levels change after treatment.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

prematurely born infants with retinopathy of prematurity requiring treatment

Retinopathy of Prematurity (ROP)
Not Provided
  • ROP infants treated with intravitreal anti-VEGF agents
  • ROP infants treated with retinal laser photocoagulation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
Not Provided
March 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of retinopathy of prematurity requiring treatment

Exclusion Criteria:

  • Anemia
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01470430
VISOR Study
No
Andreas Stahl, MD, University Hospital Freiburg
University Hospital Freiburg
Not Provided
Principal Investigator: Andreas Stahl, MD University Eye Hospital Freiburg, Germany
University Hospital Freiburg
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP